本研究將超順磁氧化鐵均勻的注射到腫瘤中，並使用交流的磁場加熱超順磁氧化鐵連帶的成功殺死癌細胞並消除腫瘤，且減少傷害正常組織的生長，此種療法屬於所謂的高溫療法(Hyperthermia)，所使用的超順磁氧化鐵為可以注射到人體的磁振造影造影劑”Resovist”。體外實驗的部分驗證了該種的超順磁氧化鐵在交流磁場下具備殺死癌細胞的溫度，動物實驗則使用多種方法抑制和消除腫瘤。

本研究設計了一個溫度回饋系統，可以準確的利用交流磁場快速的加熱超順磁氧化鐵到固定的溫度，且溫度變異小於0.2oC，利用該溫度回饋系統加熱本研究中所使用的CT-26直腸癌細胞到37、40、42、 45、 46、47oC探討各個溫度點對於該細胞的影響以及發現當該細胞被加熱到45oC時可以確實殺死該種癌細胞。

動物實驗則成功的局部加熱大鼠鼠肝到59.5 oC，且沒有涵蓋超順磁氧化鐵的部位溫度為37 oC，驗證了使用超順磁氧化鐵局部加熱的可能性。最後使用了多種方法注射超順磁氧化鐵到種有CT-26癌細胞的小鼠腫瘤上，從初期的些微抑制，到中期使用濃縮超順磁氧化鐵大幅的抑制腫瘤生長，最後使用擠壓式幫浦以低流速均勻注射超順磁氧化鐵到腫瘤中成功消除腫瘤，驗證本療法的可行性。

研究目標除了殺死癌細胞消除腫瘤外，目的是將此療法順利應用到臨床醫學上，所使用的藥品皆為可注射到人體身上。所以可以預期的是由於本療法具備局部治療的優點，如果本療法運用在臨床上，病人在治療過程中可以減輕痛苦減少副作用，本新式療法在於治療惡性腫瘤上具有極大的潛力。

[Background and Aims] Cancer is still a major threat to our people and its therapy needs further improvement. Magnetic nanoparticles induced hyperthermia offers a new hope for these patients. We conducted in vitro and in vivo experiments to assess the feasibility of this new form of thermotherapy. [Material and Methods] FDA approved contrast medium for magnetic resonance imaging—ferucarbotran (Resovist○R), was used in our experiments. We set up an instrument which can generate high-frequency magnetic field to induce a localized temperature increase induced by injecting ferucarbotran to the tumors. A feedback temperature control system was successfully developed to keep the nanoparticles at a constant temperature to prevent overheating the targeted cells or animal tumors. For in vitro tests, the relationship between temperature rise and cell survival rate was first investigated. For in vivo tests, murine colon cancer cells were inoculated to the mice. The tumor bearing mice were treated with nanoparticles (resovist) injection and receiving alternating magnetic field induced thermotherapy. Tumor size and survival were observed and recorded. In addition, we did experiments on rodent liver tumors. [Results] By using the feedback temperature control system, superparamagnetic nanoparticles could be heated up to specific temperatures, 37, 40, 42, 45, 46 and 47 oC, respectively, with a variation less than 0.2 oC. With this approach, we found the survival rate of cancer cells would be greatly reduced while CT-26 colon cancer cells were heated above 45oC. Besides, temperatures increase up to 59.5oC can be successfully generated in rodent livers. In-vivo tests also indicated that hyperthermia cancer therapy using this approach could significantly suppress the tumor growth; moreover, complete regression of tumor was achieved by improving our injection technique. The treated animals are free from cancer for a prolonged observation period (90 days). [Discussion] Magnetic nanoparticles induced hyperthermia is very promising to treat cancer successfully. Our system can generate enough heat to kill cancer cells and feedback control device can prevent the possible unwanted side effects. Our studies can provide evidences for further clinical trials.

[1]. Z. J. Van, “Heating the patient: a promising approach?,” Annals of Oncology, Vol. 13, pp. 1173-1184, 2002.

[2]. G. B. Stillwagon, W. E. Order, C. Guse, J. L. Klein, P. K. Leichner, S. A. Leibel, Fishman EK , M. P. Carey and T. G. Burish, “Etiology and treatment of the psychological side-effects associated with cancer-chemotherapy- a critical-review and discussion,” Psychological Bulletin, Vol. 104, pp. 307-325, 1988.

[3]. T. G. Burish and M. P. Carey, ”Conditioned aversive responses in cancer-chemotherapy patients - theoretical and developmental analysis,” Journal of consulting and clinical psychologu, Vol. 54, pp. 593-600, 1986.

[4]. G. B. Stillwagon, S. E. Order, C. Guse, J. L. Klein, P. K. Leichner, S. A. Leibel and E. K. Fishman, “194 Hepatocellular cancers treated by radiation and chemotherapy combinations - toxicity and response, a radiation-therapy oncology group-study,” International Journal of radiation oncology biology physics, Vol. 17, pp. 1223-1229, 1989.

[5]. J. Seong, K. C. Keum, K. H. Han, D. Y. Lee, J. T. Lee, C. Y. Chon, Y. M. Moon, C. O. Suh and G. E. Kim, “Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma,” International Journal Of Radiation Oncology Biology Physics, Vol. 43, pp. 393-397, 1999.

[6]. R. E. Welling and K. Lamping, “Cryoprobe as a handle for resection of metastatic liver tumors,” Journal of Surgery Oncology, Vol. 45, pp. 227-228, 1990.

[7]. P. Bayjoo, R. C. Rees and J. R. Goepel, “Natural killer cell activity following cryosurgery of normal and tumour bearing liver in an animal model,” Journal of Clinical Immunology, Vol. 35, pp. 129-132, 1991.

[8]. L. F. Fajardo, “Pathological effects of hyperthermia in normal-tissues,” Cancer Research, Vol. 44, pp. 4826-4835. 1984.

[9]. P. Sminia, J. Vanderzee, J. Wondergem and J. Haveman, “A Review- Effect of hyperthermia on the central-nervous-system,” International Journal of Hyperthermia, Vol. 10, pp. 1-30, 1994.

[10]. J. R. FIKE, G. T. Gobbel, T. Satoh and P. R. Stauffer, “Normal brain response after interstitial microwave hyperthermia,” International Journal of hyperthermia”, Vol. 7, pp. 795-808, 1991.

[11]. J. W. Valvano, J. R. Cochran and K. R. Diller, “Thermal conductivity and diffusivity of biomaterials measured with self-heating thermistors,” International Journal of Themophys, Vol. 6, pp. 301-311, 1985.

[12]. S. Shiina, K. Tagawa and T. Unuma, “Percutaneous ethanol injection therapy for hepatocellular carcinoma: A histopathology study,” Cancer, Vol. 68, pp. 1524-1530, 1991.

[13]. T. Takayama, T. Sekine and M. Makuuchi, “Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial,” Lancet, Vol. 356, pp. 802-807, 2000.

[14]. H. M. Goldstein, “Transcatheter occlusion of abdominal tumors,” Radiology, Vol. 120, pp. 539-545, 1976.

[15]. S. A. Rosenberg, 2000, “Principle and practice of the biologic therapy of cancer”, Philadelphia, Lippincott Williams & Wilkins.

[16]. R. T. Gordon, J. R. Hines and D. Gordon, “Intracellular hyperthermia – a biophysical approach to cancer via intracellular temperature and biophysical alterations,” Medical Hypotheses, Vol. 5, pp. 83-103, 1979.

[17]. A. Jordan, P. Wust, H. Fahling, W. John, A. Hinz and R. Felix, “Inductive heating of ferromagnetic particles and magnetic fluid: physical evaluation of their potential for hyperthermia,” International Journal of Hyperthermia, Vol. 9, pp. 51-68, 1993.

[18]. L. Shen, P. E. Laibinis and T. A. Hatton, “Bilayer surfactant stabilized magnetic fluids: synthesis and interactions at interface,” Langmuir, Vol. 15, pp. 47-53, 1999.

[19]. F. Y. Cheng, C. H. Su, Y. S. Yang, C. S. Yeh, C. Y. Tsai, C. L. Wu, M. T. Wu and D. B. Shieh, “Characterization of aqueous dispersions of Fe3O4 nanoparticles and their biomedical applications,” Biomaterials, Vol. 26, pp. 729-738, 2005.

[20]. T. Neuberger, B. Schopf, H. Hofmann, M. Hofmann and B. von Rechenberg, “Review-Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system,” Journal of Magnetism and Magnetic Materials, Vol. 293, pp.483-496, 2005.

[21]. C. C. Berry and A. S. G. Curtis, “TOPICAL REVIEW- Funtionalisation of magnetic nanoparticles for applications in biomedicine,” Journal of Physics D: Applied Physics, Vol. 36, pp. 198-206, 2003.

[22]. A. Kawamata, Z. X. Na and Y. Fujiki, “Gd-DTPA enhanced MRI for the oral and maxillofacial cystic lesion,” Oral Radiology, Vol. 8, pp. 33-39, 2006.

[23] J. K. Widder, A. E. Senyei and D. G. Scarpelli, “Magnetic microspheres: a model system for site specific drug delivery in vivo,” Proceedings of the Society for Experimental Biology & Medicine, Vol. 58, pp. 141-145, 1978.

[24]. M. Suzuki, M. Shinkai, M. Yanase, A. Ito, H. Honda and T. Kobayashi, “Enhancement of uptake of magnetoliposome by magnetic force and hyperthermic effect on tumor,” Japanese Journal of Hyperthermic Oncology, Vol. 15, pp. 79-87, 1999.
[25]. J. L. Guesdon, R. Thiery and S. Avrameas, “Magnetic enzyme immunoassay for measuring human IgE,” Journal of Allergy Clinical Immunology, Vol. 6, pp. 23-27, 1978.

[26]. W. Dungchai, W. Siangproh, J. M. Lin, O. Chailapakul, S. Lin and X. Ying, “Development of a sensitive micro-magnetic chemiluminescence enzyme immunoassay for the determination of carcinoembryonic antigen,” Anal Bioanalysis Chemical, Vol. 387, pp. 1965-1971, 2007.

[27]. A. Ito, H. Hoinda and T. Kobayashi, “Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expression,” Cancer Immunol Immunother, Vol. 55, pp. 320-328, 2006.

[28]. A. Ito, M. Shinkai, H. Honda, K. Yoshikawa, S. Saga, T. Wakabayashi, J. Yoshida and T. Kobayashi, ”Heat shock protein 70 expression induces an antitumor immunity during intracellular hyperthermia using magnetite nanoparticles,” Cancer Gene Therapy, Vol. 52, pp. 80-88, 2003.

[29]. M. Yanase, M. Shinkai, H. Honda, T. Wakabayashi, J. Yoshida and T. Kobayashi, “Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes,” Japanese Journal of Cancer Research, Vol. 89, pp. 775-782, 1998.

[30]. M. Babincova, P. Sourivong, D. Leszczynska and P. Babinec, “Blood-specific whole- body electromagnetic hyperthermia,” Medical Hypotheses, Vol. 55, pp. 459-460 ,2000.

[31]. M. Babincova, P. Cicmanec, V. Altanerova, C. Altaner and P. Babinec, “AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy,” Bioelectrochemistry, Vol. 55, pp. 17-19, 2001.

[32]. M. Babincova, V. Altanerova, C. Altaner, P. Cicmanec and P. Babinec, “In vivo heating of magnetic nanoparticles in alternating magnetic field,” Medical Physics, Vol. 31, pp. 2219-2221 ,2004.

[33]. Y. G. Lv, Z. S. Deng and J. Liu, “3-D numerical study on the induced heating effects of embedded micro/nanoparticles on human body subject to external medical electromagnetic field,” IEEE Transactions On Nanbioscience, Vol. 4, pp. 284-294, 2005.

[34] A. Ito, M. Shinkai, H. Honda, T. Wakabayashi, J. Yoshida and T. Kobayashi “Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia,” Cancer Immunology and Immunotherapy, Vol. 50, pp. 515-522, 2001.

[35]. A. Ito, K. Tanaka, K. Kondo, M. Shinkai, H. Honda, K. Matsumoto, T. Saida and T. Kobayashi, “Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma,” Cancer Science, Vol. 94, pp. 308-313, 2003.

[36]. N. Kawai, A. Ito, Y. Nakahara, H. Honda, T. Kobayashi, M. Futakuchi, T. Shirai, K. Tozawa, and K. Kohri, ”Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core,” The Prostate, Vol. 66, pp. 718-727, 2006.

[37]. A. Ito, K. Tanaka, H. Honda, S. Abe, H. Yamaguchi and Takeshi Kobayashi, “Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles,” Journal of Bioscience and Bioengineering, Vol. 96, pp. 364-369, 2003.

[38]. X. Z. Zhang, P. J. Lewis, and C. C. Chu, “Fabrication and characterization of a smart drug delivery system: microsphere in hydrogel,” Biomaterials, Vol. 26, pp. 3299-3309, 2005.

[39].Y. Y. Liu and X. D. Fun, “Synthesis and characterization of pH- and temperature sensitive hydrogel of N-ispropylacrylamide/cyclodextrin based copolymer,” Polymer, Vol. 43, pp. 4997-5003, 2002.